SavedAdd your journal

Journals / Erciyes Medical Journal / 2021 / Cilt: 43 - Sayı: 6

Comparing the Clinical, Radiological and Laboratory Characteristics of Confirmed or Suspected COVID-19 Cases

Oğuz GÜNDOĞDU
Onur AVCI
Pages
585–593
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: The mean symptom duration was 5.78 days in Group 1, 2.67 days in Group 2, and 5.26 days in Group 3 (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The present study aims to compare the clinical and laboratory characteristics of patients diagnosed with coronavirus disease (COVID-19) using Real-Time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and Computed Tomography (CT).
📊
Key Findings & Data:Materials and Methods: In this study, 240 adult patients were included.
💡
Conclusion & Impact:Results: The mean symptom duration was 5.78 days in Group 1, 2.67 days in Group 2, and 5.26 days in Group 3 (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The present study aims to compare the clinical and laboratory characteristics of patients diagnosed with coronavirus disease (COVID-19) using Real-Time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and Computed Tomography (CT). Materials and Methods: In this study, 240 adult patients were included. The demographic data, symptoms, COVID-19 findings in the initial pulmonary CT during admission and the first laboratory parameters were recorded. The patients were divided into three groups as Group 1 consisting of 100 PCR (+) CT (+) patients, Group 2 consisting of 40 PCR (+) CT (-) patients, Group 3 consisting of 100 PCR (-) CT (+) patients. Results: The mean symptom duration was 5.78 days in Group 1, 2.67 days in Group 2, and 5.26 days in Group 3 (p

🔖

Cite This Article

GÜNDOĞDU, O., AVCI, O. (2022). Comparing the Clinical, Radiological and Laboratory Characteristics of Confirmed or Suspected COVID-19 Cases. Erciyes Medical Journal, Cilt: 43 - Sayı: 6, 585–593. https://ajindex.com/articles/502208

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497–506
  2. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020; 55(3): 105924
  3. Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int J Surg 2020; 78: 185–93 4. Yang Y, Yang M, Shen C, Wang F, Yuan J, Li J, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. MedRxiv February 17, 2020. doi: 10.1101/2020.02.11.20021493
  4. Aktas, Gulali. A comprehensive review on rational and effective treatment strategies against an invisible enemy; SARS Cov-2 infection. Exp Biomed Res 2020; 3(4): 293–311
  5. Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology 2020; 295(1): 202–7
  6. Huang P, Liu T, Huang L, Liu H, Lei M, Xu W, et al. Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion. Radiology 2020; 295(1): 22–3
  7. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical coronavirus disease 2019 (COVID-19) pneumonia: Relationship to negative RT-PCR testing. Radiology 2020; 296(2): E41–5
  8. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases. Radiology 2020; 296(2): E32–40
  9. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395(10229): 1033–4
  10. Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect 2020; 50(4): 332–4
  11. Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol 2020; 84: 106504
  12. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta 2020; 505: 190–1
  13. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological